Paul Sauer Biography and Net Worth

SVP of Vaxcyte

Paul has over 30 years of experience industrializing biologics for numerous biotechnology companies. Prior to joining Vaxcyte, Paul was VP of Process Sciences & Manufacturing at Igenica Biotherapeutics, where he initiated the company’s development activities and built its supply chain network for GMP manufacturing of its antibody drug conjugates. Prior to that, Paul was Senior Director of Process Development at OncoMed Pharmaceuticals, where he contributed to multiple IND filings for the company’s antibody-based oncology therapies. He also held various process, engineering, scale-up, and manufacturing positions at Protein Design Labs, Scios, and Genentech. Through the years, Paul has contributed to numerous approved biologics, including Genentech’s Activase® and Pulmozyme®. He also contributed significantly to the development of the patented high-yield process that formed the basis for production of Abbvie and Biogen’s ZinbrytaTM, a humanized antibody approved for the treatment of Multiple Sclerosis. Paul earned an MBA at Santa Clara University and a BS in Genetics from the University of California, Davis. Paul enjoys spending quality time with his family and helping his wife with her non-profit organization focused on transforming health through diet.

What is Paul Sauer's net worth?: The estimated net worth of Paul Sauer is at least $1.26 million as of August 22nd, 2022. Mr. Sauer owns 14,687 shares of Vaxcyte stock worth more than $1,262,495 as of November 20th. This net worth evaluation does not reflect any other assets that Mr. Sauer may own. Additionally, Mr. Sauer receives an annual salary of $608,960.00 as SVP at Vaxcyte. Learn More about Paul Sauer's net worth.
How old is Paul Sauer?: Mr. Sauer is currently 63 years old. There are 7 older executives and no younger executives at Vaxcyte. Learn More on Paul Sauer's age.
What is Paul Sauer's salary?: As the SVP of Vaxcyte, Inc., Mr. Sauer earns $608,960.00 per year. There are 3 executives that earn more than Mr. Sauer. The highest earning executive at Vaxcyte is Mr. Grant E. Pickering M.B.A., Co-Founder, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Paul Sauer's salary.
How do I contact Paul Sauer?: The corporate mailing address for Mr. Sauer and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Paul Sauer's contact information.
Has Paul Sauer been buying or selling shares of Vaxcyte?: Paul Sauer has not been actively trading shares of Vaxcyte during the last ninety days. Most recently, Paul Sauer sold 3,000 shares of the business's stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $25.93, for a transaction totalling $77,790.00. Following the completion of the sale, the senior vice president now directly owns 14,687 shares of the company's stock, valued at $380,833.91. Learn More on Paul Sauer's trading history.
Who are Vaxcyte's active insiders?: Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.
Are insiders buying or selling shares of Vaxcyte?: In the last year, insiders at the sold shares 48 times. They sold a total of 430,090 shares worth more than $33,820,640.21. The most recent insider tranaction occured on November, 7th when CEO Grant Pickering sold 2,366 shares worth more than $245,803.74. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.
Information on this page was last updated on 11/7/2024.

Paul Sauer Insider Trading History at Vaxcyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2022	Sell	3,000	$25.93	$77,790.00	14,687
7/27/2022	Sell	3,000	$25.00	$75,000.00	17,687
7/20/2022	Sell	3,000	$25.00	$75,000.00	20,687
5/23/2022	Sell	3,000	$26.22	$78,660.00	23,687
4/22/2022	Sell	3,000	$25.00	$75,000.00	25,125
3/22/2022	Sell	3,000	$25.00	$75,000.00
3/10/2022	Sell	6,000	$25.00	$150,000.00
12/29/2021	Sell	6,000	$25.00	$150,000.00
9/22/2021	Sell	5,307	$25.20	$133,736.40
2/11/2021	Sell	2,500	$26.65	$66,625.00	80,399
1/11/2021	Sell	2,500	$26.21	$65,525.00

Paul Sauer Buying and Selling Activity at Vaxcyte

Vaxcyte Company Overview

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Today's Range

Now: $85.96

$85.18

$88.07

50 Day Range

MA: $108.95

$85.96

$117.93

2 Week Range

Now: $85.96

$48.24

$121.06

Volume

1,716,699 shs

Average Volume

1,467,248 shs

Market Capitalization

$10.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

Paul Sauer Biography and Net Worth

What is Paul Sauer's net worth?

How old is Paul Sauer?

What is Paul Sauer's salary?

How do I contact Paul Sauer?

Has Paul Sauer been buying or selling shares of Vaxcyte?

Who are Vaxcyte's active insiders?

Are insiders buying or selling shares of Vaxcyte?